GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (NAS:SAVA) » Definitions » Asset Turnover

Cassava Sciences (Cassava Sciences) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Cassava Sciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Cassava Sciences's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Cassava Sciences's Total Assets for the quarter that ended in Dec. 2023 was $162.10 Mil. Therefore, Cassava Sciences's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Cassava Sciences's annualized ROE % for the quarter that ended in Dec. 2023 was -57.20%. It is also linked to ROA % through Du Pont Formula. Cassava Sciences's annualized ROA % for the quarter that ended in Dec. 2023 was -51.62%.


Cassava Sciences Asset Turnover Historical Data

The historical data trend for Cassava Sciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences Asset Turnover Chart

Cassava Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cassava Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cassava Sciences's Asset Turnover

For the Biotechnology subindustry, Cassava Sciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cassava Sciences's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cassava Sciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Cassava Sciences's Asset Turnover falls into.



Cassava Sciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Cassava Sciences's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (234.834+151.663)/ 2 )
=0/193.2485
=0.00

Cassava Sciences's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (172.529+151.663)/ 2 )
=0/162.096
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Cassava Sciences  (NAS:SAVA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Cassava Sciences's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-83.676/146.2915
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-83.676 / 0)*(0 / 162.096)*(162.096/ 146.2915)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.108
=ROA %*Equity Multiplier
=-51.62 %*1.108
=-57.20 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Cassava Sciences's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-83.676/162.096
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-83.676 / 0)*(0 / 162.096)
=Net Margin %*Asset Turnover
= %*0
=-51.62 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Cassava Sciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Cassava Sciences (Cassava Sciences) Business Description

Traded in Other Exchanges
Address
6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.
Executives
Sanford Robertson director ONE LETTERMAN DRIVE, BUILDING C SUITE 410, SAN FRANCISCO CA 94129
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Robert Christopher Cook officer: SVP & General Counsel 6801 N. CAPITAL OF TEXAS HWY, BUILDING 1, SUITE 300, AUSTIN TX 78731
James William Kupiec officer: Chief Clinical Dev. Officer 7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN TX 78731
Eric Schoen officer: Chief Financial Officer 7801 N. CAPITAL OF TX HWY, SUITE 260, AUSTIN TX 78731
Remi Barbier director, 10 percent owner, officer: CEO, Chairman of the Board
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
O Donnell Michael J director
Robert Z Gussin director
Scannon Patrick J Md Phd director C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Nadav Friedmann director, officer: Chief Scientific Officer
Sabretooth Master Fund, L.p. 10 percent owner 405 LEXINGTON AVENUE, 50TH FLOOR, NEW YORK NY 10174